JP7606591B2 - Ｍｔｏｒｃ１モジュレーターおよびその使用 - Google Patents

Ｍｔｏｒｃ１モジュレーターおよびその使用 Download PDF

Info

Publication number
JP7606591B2
JP7606591B2 JP2023502874A JP2023502874A JP7606591B2 JP 7606591 B2 JP7606591 B2 JP 7606591B2 JP 2023502874 A JP2023502874 A JP 2023502874A JP 2023502874 A JP2023502874 A JP 2023502874A JP 7606591 B2 JP7606591 B2 JP 7606591B2
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
independently selected
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023502874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530778A5 (https=
JP2023530778A (ja
Inventor
ジョン キンケイド，
Original Assignee
エオビアン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エオビアン ファーマシューティカルズ， インコーポレイテッド filed Critical エオビアン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023530778A publication Critical patent/JP2023530778A/ja
Publication of JP2023530778A5 publication Critical patent/JP2023530778A5/ja
Priority to JP2024218609A priority Critical patent/JP7645431B2/ja
Application granted granted Critical
Publication of JP7606591B2 publication Critical patent/JP7606591B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Burglar Alarm Systems (AREA)
  • Pyridine Compounds (AREA)
JP2023502874A 2020-03-27 2021-03-26 Ｍｔｏｒｃ１モジュレーターおよびその使用 Active JP7606591B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218609A JP7645431B2 (ja) 2020-03-27 2024-12-13 Ｍｔｏｒｃ１モジュレーターおよびその使用

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063001144P 2020-03-27 2020-03-27
US202063001177P 2020-03-27 2020-03-27
US202063001187P 2020-03-27 2020-03-27
US63/001,187 2020-03-27
US63/001,144 2020-03-27
US63/001,177 2020-03-27
US202063019176P 2020-05-01 2020-05-01
US63/019,176 2020-05-01
US202063054768P 2020-07-21 2020-07-21
US202063054763P 2020-07-21 2020-07-21
US202063054762P 2020-07-21 2020-07-21
US63/054,762 2020-07-21
US63/054,763 2020-07-21
US63/054,768 2020-07-21
PCT/US2021/024536 WO2021195599A1 (en) 2020-03-27 2021-03-26 Mtorc1 modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218609A Division JP7645431B2 (ja) 2020-03-27 2024-12-13 Ｍｔｏｒｃ１モジュレーターおよびその使用

Publications (3)

Publication Number Publication Date
JP2023530778A JP2023530778A (ja) 2023-07-19
JP2023530778A5 JP2023530778A5 (https=) 2024-04-04
JP7606591B2 true JP7606591B2 (ja) 2024-12-25

Family

ID=77892684

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023502874A Active JP7606591B2 (ja) 2020-03-27 2021-03-26 Ｍｔｏｒｃ１モジュレーターおよびその使用
JP2024218609A Active JP7645431B2 (ja) 2020-03-27 2024-12-13 Ｍｔｏｒｃ１モジュレーターおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218609A Active JP7645431B2 (ja) 2020-03-27 2024-12-13 Ｍｔｏｒｃ１モジュレーターおよびその使用

Country Status (11)

Country Link
US (3) US11634432B2 (https=)
EP (1) EP4126229A4 (https=)
JP (2) JP7606591B2 (https=)
KR (2) KR20250065937A (https=)
CN (2) CN115776907B (https=)
AU (2) AU2021241718B2 (https=)
CA (1) CA3173722A1 (https=)
IL (1) IL296828A (https=)
MX (1) MX2022011964A (https=)
WO (1) WO2021195599A1 (https=)
ZA (1) ZA202210888B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
CN121426814A (zh) * 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途
EP4688148A1 (en) * 2023-04-07 2026-02-11 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014387A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
US20190031683A1 (en) 2015-09-11 2019-01-31 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US6187757B1 (en) * 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
WO2006136175A2 (en) 2005-06-22 2006-12-28 Lifecycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
GB0601406D0 (en) 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
US20110098241A1 (en) 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
CN103391780B (zh) * 2011-02-16 2015-08-19 诺瓦提斯公司 用于治疗神经变性疾病的治疗剂的组合物
US20160138027A1 (en) * 2013-03-14 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
ES2857226T3 (es) * 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
JP6793652B2 (ja) 2015-09-03 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
CN108926533B (zh) 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
US10478561B2 (en) 2017-08-03 2019-11-19 Minhong Yu Wireless transmission system with integrated sensing capability
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
WO2020076738A2 (en) 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
HRP20250197T1 (hr) 2018-12-18 2025-04-11 Novartis Ag Derivati rapamicina
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
CN121426814A (zh) 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途
US20220267352A1 (en) 2021-01-22 2022-08-25 Anakuria Therapeutics, Inc. Rapamycin analogs and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
WO2001014387A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US20190031683A1 (en) 2015-09-11 2019-01-31 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用

Also Published As

Publication number Publication date
US11603377B2 (en) 2023-03-14
CN115776907A (zh) 2023-03-10
US20220235069A1 (en) 2022-07-28
AU2025204768A1 (en) 2025-07-17
US20240002399A1 (en) 2024-01-04
CA3173722A1 (en) 2021-09-30
KR20250065937A (ko) 2025-05-13
JP7645431B2 (ja) 2025-03-13
WO2021195599A1 (en) 2021-09-30
EP4126229A1 (en) 2023-02-08
KR20230084095A (ko) 2023-06-12
AU2025204768B2 (en) 2025-08-07
CN119954829A (zh) 2025-05-09
AU2025204768C1 (en) 2026-02-05
IL296828A (en) 2022-11-01
US11634432B2 (en) 2023-04-25
AU2021241718A1 (en) 2022-10-20
AU2021241718B2 (en) 2025-03-27
CN115776907B (zh) 2025-02-25
BR112022019508A2 (pt) 2022-11-16
MX2022011964A (es) 2022-12-02
JP2025028197A (ja) 2025-02-28
EP4126229A4 (en) 2024-04-17
US20220332727A1 (en) 2022-10-20
KR102805250B1 (ko) 2025-05-08
ZA202210888B (en) 2024-02-28
JP2023530778A (ja) 2023-07-19

Similar Documents

Publication Publication Date Title
JP7645431B2 (ja) Ｍｔｏｒｃ１モジュレーターおよびその使用
CN116322677B (zh) Mtorc1调节剂及其用途
CA3042710A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
CN110191878A (zh) 疾病治疗用双亮氨酸拉链（dlk）激酶的二环[1.1.1]戊烷抑制剂
CA3120514A1 (en) Cyclic ureas
JP2014526560A (ja) β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
JP2022553273A (ja) 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤
AU2016233202A1 (en) Heterocyclic compounds useful as inhibitors of TNF
US9725469B2 (en) Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
BR112022019508B1 (pt) MODULADORES DE mTORC1 E SEUS USOS
BR122024006050B1 (pt) MODULADORES DE mTORC1 E SEUS USOS
BR122024006050A2 (pt) Moduladores de mtorc1 e seus usos
HK40096020B (zh) Mtorc1调节剂及其用途
HK40096020A (zh) Mtorc1调节剂及其用途
KR20200112910A (ko) 도파민 d3 수용체 길항 작용을 갖는 축환 화합물
WO2025185736A1 (zh) 一种多元螺环化合物的晶型、其制备方法和医药用途
WO2025185734A1 (zh) 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240325

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241213

R150 Certificate of patent or registration of utility model

Ref document number: 7606591

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150